Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 95, Issue 1, 2012, Pages 132-138

  Akbarzadeh, Samad ^a   Nabipour, Iraj ^a   Jafari, Seyed Mojtaba ^a   Movahed, Ali ^a   Motamed, Niloofar ^a   Assadi, Majid ^a   Hajian, Najmeh ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipocytokine; Beta cell; Diabetes mellitus; Insulin resistance; Insulin sensitivity; Obesity

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL; VASPIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RELATIVE; SEX RATIO; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FAMILY; FEMALE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; IRAN; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SERPINS;

EID: 84355162933     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.10.004     Document Type: Article

References (47)

1. Lago F., Gómez R., Gómez-Reino J.J., Dieguez C., Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci 2009, 34:500-510.
2. Kralisch S., Bluher M., Paschke R., Stumvoll M., Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007, 7:39-45.
3. Gulcelik N.E., Usman A., Gürlek A. Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 2009, 36:397-403.
4. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
5. Haider D.G., Schaller G., Kapiotis S., Maier C., Luger A., Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006, 49:1909-1914.
6. Xie H., Tang S.Y., Luo X.H., Huang J., Cui R.R., Yuan L.Q., et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007, 80:201-210.
7. Katwa L.C., Seidel E.R. Visfatin in pregnancy: proposed mechanism of peptide delivery. Amino Acids 2009, 37:555-558.
8. Saddi-Rosa P., Oliveira C.S., Giuffrida F.M., Reis A.F. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010, 2:21.
9. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91:295-299.
10. Sandeep S., Velmurugan K., Deepa R., Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007, 56:565-570.
11. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007, 76:24-29.
12. Zhu J., Schott M., Liu R., Liu C., Shen B., Wang Q., et al. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 2008, 40:801-805.
13. Lewandowski K.C., Stojanovic N., Press M., Tuck S.M., Szosland K., Bienkiewicz M., et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007, 50:1033-1037.
14. Krzyzanowska K., Krugluger W., Mittermayer F., Rahman R., Haider D., Shnawa N., et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006, 110:605-609.
15. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007, 56:451-458.
16. Song H.K., Lee M.H., Kim B.K., Park Y.G., Ko G.J., Kang Y.S. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008, 295:F1485-F1494.
17. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008, 17:327-333.
18. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610-10615.
19. Eriksson J., Franssila-Kallunki A., Ekstrand A., Saloranta C., Widen, Schalin C., et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989, 321:337-343.
20. Knowles N.G., Landchild M.A., Fujimoto W.Y., Kahn S.E.S.O. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2002, 25:292-297.
21. Perseghin G., Ghosh S., Gerow K., Shulman G.I. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997, 46:1001-1009.
22. Nabipour I., Amiri M., Imami S.R., Jahfari S.M., Shafeiae E., Nosrati A., et al. The metabolic syndrome and nonfatal ischemic heart disease; a population-based study. Int J Cardiol 2007, 118:48-53.
23. Carnevale Schianca G.P., Rossi A., Sainaghi P.P., Maduli E., Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 2003, 26:1333-1337.
24. Stephens J.M., Vidal-Puig A.J. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006, 17:128-131.
25. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Retraction. Science 2007, 318:565.
26. Brown J.E., Onyango D.J., Ramanjaneya M., Conner A.C., Patel S.T., Dunmore S.J., et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010, 44:171-178.
27. Berndt J., Klöting N., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
28. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91:3165-3170.
29. Hammarstedt A., Pihlajamäki J., Rotter Sopasakis V., Gogg S., Jansson P.A., Laakso M., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006, 91:1181-1184.
30. Toruner F., Altinova A.E., Bukan N., Arslan E., Akbay E., Ersoy R., et al. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. Horm Res 2009, 72:33-37.
31. Chan T.F., Chen Y.L., Lee C.H., Chou F.H., Wu L.C., Jong S.B., et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006, 13:364-367.
32. Warram J.H., Martin B.C., Krolewski A.S., Soeldner J.S., Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990, 113:909-915.
33. Stadler M., Pacini G., Petrie J., Luger A., Anderwald C. Beta cell (dys)function in non-diabetic offspring of diabetic patients. Diabetologia 2009, 52:2435-2444. RISC Investigators.
34. Revollo J.R., Körner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
35. Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004, 279(3):50754-50763.
36. López-Bermejo A., Chico-Julià B., Fernàndez-Balsells M., Recasens M., Esteve E., Casamitjana R., et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006, 55:2871-2875.
37. Zahorska-Markiewicz B., Olszanecka-Glinianowicz M., Janowska J., Kocełak P., Semik-Grabarczyk E., Holecki M., et al. Serum concentration of visfatin in obese women. Metabolism 2007, 56:1131-1134.
38. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581.
39. Chang Y.C., Chang T.J., Lee W.J., Chuang L.M. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010, 59:93-99.
40. Chen C.C., Li T.C., Li C.I., Liu C.S., Lin W.Y., Wu M.T., et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007, 56:1216-1220.
41. Wang P., van Greevenbroek M.M., Bouwman F.G., Brouwers M.C., van der Kallen C.J., Smit E., et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007, 454:971-976.
42. Klöting N., Berndt J., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006, 339:430-436.
43. Wang Y.M., Wang W.P., Wang L.P., Lü Q.H., Zhou X.H. Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha. Chin Med J (Engl) 2010, 123:936-941.
44. El-Mesallamy H.O., Kassem D.H., El-Demerdash E., Amin A.I. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2010, June 1 [Epub ahead of print].
45. Youn B.S., Klöting N., Kratzsch J., Lee N., Park J.W., Song E.S., et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57:372-377.
46. Chang H.M., Park H.S., Park C.Y., Song Y.S., Jang Y.J. Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metabolism 2010, 59:1276-1281.
47. Song Y., Manson J.E., Tinker L., Howard B.V., Kuller L.H., Nathan L., et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care 2007, 30:1747-1752.